Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2725 Upfront Surgery in Patients with High-Grade GEP NEN and MINEN: A Nordic Multicenter Study of 201 Patients

Introduction: Surgery is the principal treatment for loco-regional gastroenteropancreatic (GEP) neuroendocrine tumors (NET). However, whether surgery is beneficial in high-grade neuroendocrine neoplasms (NEN) and mixed neuroendocrine-non neuroendocrine neoplasms (MiNEN) is not known.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Pommergaard H

Authors: Pommergaard H, Nielsen K, Sorbye H, Federspiel B, Tabaksblat E,

Keywords: surgery, neuroendocrine carcinoma, MiNEN, neuroendocrine neoplasms, survival, gastroenteropancreatic,

#2708 Patient Reported Symptoms, Coping and Quality of Life during Somatostatin Analogue Treatment for Metastatic Small-Intestinal Neuroendocrine Tumours

Introduction: Patients with metastatic small-intestinal neuroendocrine tumours (NET) have been shown to have a reduced quality of life compared to the general population and many have disabling symptoms during somatostatin analogue (SSA) treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Sorbye H

Authors: Sorbye H, Meyer L, Mordal K, Myhre S, Thiis-Evensen E,

Keywords: Quality of life, small-intestinal neuroendocrine tumors, patient reported symptoms, coping, somatostatin analogue,

#1783 Gastroenteropancreatic High-Grade Neuroendocrine Carcinomas: A SEER Database Analysis of 6291 Cases

Introduction: Knowledge about gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) is scarce given their low incidence rates and aggressive clinical behavior

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Dasari A, Mehta K, Sorbye H, Yao J,

Keywords: Grade 3, NE carcinoma,

#314 Clinical Effect of Temozolomide-Based Chemotherapy in Poorly Differentiated Endocrine Carcinoma (PDEC) after Progression on First-Line Chemotherapy

Introduction: Patients with metastatic PDEC usually have a short survival. After first-line palliative chemotherapy, there are no established second-line treatments. Temozolomide has shown effect in other NETs.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Welin S, Sorby H, Sebjornsen S, Knappskog S, Busch C,

Keywords: chemotherapy, neuroendocrine cancer, PDEC, second-line, temozolomide,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!

 

The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.